









Markets
/
Stocks
/
nasdaq-plse
/

Pulse Biosciences Inc

PLSE

20.750USD

+7.060+51.57%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

1.41BMarket Cap

LossP/E TTM



Pulse Biosciences Inc

20.750

+7.060+51.57%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Pulse Biosciences Inc

Currency: USD Updated: 2026-02-06

Key Insights

Pulse Biosciences Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 51 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 26.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Pulse Biosciences Inc's Score

Industry at a Glance

Industry Ranking

51 / 205

Overall Ranking

149 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Pulse Biosciences Inc Highlights

StrengthsRisks

Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. It is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. It is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.

Undervalued

The company’s latest PE is -18.17, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 6.12M shares, decreasing 5.88% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.11M shares of this stock.

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

23.500

Target Price

+55.53%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Pulse Biosciences Inc is 7.35, ranking 90 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.35

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.39

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.01

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.34

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Pulse Biosciences Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Pulse Biosciences Inc is 7.28, ranking 99 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -18.17, which is -92.08% below the recent high of -1.44 and -55.23% above the recent low of -28.20.

Score

Industry at a Glance

Previous score

7.28

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 51/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Pulse Biosciences Inc is 9.00, ranking 6 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 22.00, with a high of 22.00 and a low of 22.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Strong Buy

Current Rating

23.500

Target Price

+55.53%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Pulse Biosciences Inc

PLSE

Intuitive Surgical Inc

ISRG

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Pulse Biosciences Inc is 9.69, ranking 2 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 23.27 and the support level at 15.77, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.56

Change

3.13

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.841

Buy

RSI(14)

75.187

Buy

STOCH(KDJ)(9,3,3)

69.373

Buy

ATR(14)

1.294

High Vlolatility

CCI(14)

393.635

Overbought

Williams %R

0.667

Overbought

TRIX(12,20)

0.089

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

15.460

Buy

MA10

14.694

Buy

MA20

14.531

Buy

MA50

14.251

Buy

MA100

15.528

Buy

MA200

15.794

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Pulse Biosciences Inc is 3.00, ranking 134 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 9.03%, representing a quarter-over-quarter increase of 1.44%. The largest institutional shareholder is The Vanguard, holding a total of 1.11M shares, representing 1.65% of shares outstanding, with 31.90% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Duggan (Robert William)

48.79M

+0.32%

BlackRock Institutional Trust Company, N.A.

1.16M

-2.52%

The Vanguard Group, Inc.

Star Investors

1.11M

-9.02%

Zanganeh (Mahkam)

873.47K

BofA Global Research (US)

804.96K

+2.73%

Geode Capital Management, L.L.C.

469.49K

-6.00%

State Street Investment Management (US)

421.88K

+0.63%

Uecker (Darrin R)

284.62K

+0.07%

Griffin Asset Management, Inc.

227.31K

-1.02%

Northern Trust Investments, Inc.

183.69K

-4.75%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Pulse Biosciences Inc is 4.66, ranking 100 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.80. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.